Clinical trials
Alzheimer's Disease Dementia clinical trials
Below are recruiting alzheimer's disease dementia clinical trials, each written for real people, not researchers. We’re tracking 471 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05477862Enrolling by invitation
Improvised music for Alzheimer's anxiety
This study looks at how creating music in the moment (improvisation) affects anxiety and brain function in people with mild to moderate Alzheimer's disease. It may help reduce agitation and improve quality of life.
Chicago, IllinoisAges 55–100 - NCT05295615Recruiting
Pulsed magnetic treatment for mild to moderate Alzheimer’s
This trial tests whether a pulsed electromagnetic field (a non-drug device that uses magnetic pulses) can help people with mild to moderate Alzheimer’s. Participants typically stay on stable Alzheimer’s medicines and follow daily home treatments during the study.
Hackensack, New JerseyAges 50–100 - NCT03810794Recruiting
Acupuncture study for people with Alzheimer’s memory problems
This trial tests whether acupuncture can improve symptoms in people with Alzheimer’s disease. You may qualify if you have memory and thinking changes consistent with Alzheimer’s and meet imaging and brain-scan score requirements.
Shanghai, Shanghai MunicipalityAges 50–85 - NCT04902703RecruitingPhase 2
GM-CSF drug trial for mild to moderate Alzheimer’s disease
This Phase 2 study tests whether sargramostim (a GM-CSF related medicine) is safe and can slow or improve Alzheimer’s symptoms. You might be a good fit if you have mild or moderate Alzheimer’s, positive amyloid testing, and can complete frequent visits with a close caregiver who knows you well.
Aurora, ColoradoAges 60–85 - NCT04661280RecruitingPhase 3
Donepezil compared with non-drug care for Alzheimer’s
This trial compares donepezil (a medicine for Alzheimer’s symptoms) against a non-drug treatment plan. It aims to see which approach helps people with Alzheimer’s who still have measurable thinking ability and specific Alzheimer’s test results.
ParisAges 50 years+ - NCT04570085RecruitingPhase 3
Caffeine treatment to improve thinking in Alzheimer’s disease
This trial tests whether changing caffeine intake can improve thinking and brain function in people with Alzheimer’s disease. You may qualify if you can follow a low-caffeine diet and have stable Alzheimer’s treatment and sleep/heart conditions.
AmiensAges 50 years+ - NCT04575337Recruiting
Biomarker study to help detect Alzheimer’s early
This study looks for brain/biological “signals” (biomarkers) that may identify Alzheimer’s disease earlier, including stages before clear symptoms. You may be followed for about 5 years, with repeated memory and thinking testing to see how these signs relate to future diagnosis.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04576793RecruitingPhase 2
Imaging brain inflammation in Alzheimer’s and related variants over time
This Phase 2 study uses repeated brain MRI scans to track “microglial activation,” which is a marker of brain immune/inflammation activity, in different Alzheimer’s-related conditions. It may help researchers understand how brain inflammation changes over time and differs between people with these clinical variants.
New York, New YorkAges 50 years+ - NCT03592563Recruiting
Brain health follow-up study for adults
This study follows adults over time to better understand brain health and brain-related conditions. You may join if you already have certain neurological or psychiatric diagnoses, are at higher risk, or simply want to help research on maintaining brain health.
Hong KongAges 18 years+ - NCT02811653Recruiting
Brain movement and memory study in early dementia
This study looks at how “slower movement” and brain changes relate to memory and thinking problems in people with early dementia (and some related conditions). It may help researchers understand what brain differences go with these symptoms, using tests and an MRI scan.
AmiensAges 40–85 - NCT02414347Recruiting
Tau PET scan study for Alzheimer’s disease
This study uses a PET brain scan with a small injected tracer to look for “tau” protein changes linked to Alzheimer’s disease. It may help researchers better understand how tau appears in people who are cognitively normal or have mild dementia.
St Louis, MissouriAges 18 years+ - NCT00950430Enrolling by invitationPhase 4
Brain scan study for amyloid plaques in adults
This study uses brain imaging to look for amyloid plaques (abnormal protein deposits) as people age. It may help researchers better understand how these changes develop over time.
Rochester, MinnesotaAges 30–100 - NCT07701161Recruiting
At-home blood test for Alzheimer's disease
This study is developing a simple finger-prick test you can do at home to measure a blood marker related to Alzheimer's disease. It aims to make checking for Alzheimer's easier and more convenient.
Chicago, IllinoisAges 40–90 - NCT07435467Recruiting
Blood tests for brain health in older hospital patients
This trial looks at how blood biomarkers relate to thinking, daily function, and survival in older adults, including those with neurological issues or dementia. It aims to improve understanding and care for hospitalized seniors.
AnconaAges 65 years+ - NCT06869135Recruiting
Saliva testing for brain diseases
This trial is collecting saliva samples from people with Alzheimer's, Parkinson's, or other brain diseases to find new ways to diagnose them. It may help improve early detection.
Florence, FIAges 45 years+ - NCT06871839Recruiting
A study of lencanumab for early Alzheimer's disease
This trial tests an investigational drug called lencanumab for people with early Alzheimer's disease. The goal is to see if it can help with memory and thinking by targeting brain changes caused by Alzheimer's.
BeijingAges 50–90 - NCT05908695RecruitingPhase 4
GV-971 treatment for mild to moderate Alzheimer’s disease
This Phase 4 trial tests whether a medicine called sodium oligomannate (GV-971) is safe and effective for people with mild to moderate Alzheimer’s disease. It may help slow or improve memory and thinking symptoms while carefully tracking side effects.
Huainan, AnhuiAges 50–85 - NCT07869238Recruiting
Safety study of NMS-01 for mild to moderate Alzheimer's disease
This trial tests a new treatment called NMS-01 for people with mild to moderate Alzheimer's disease. It aims to see if it's safe and may help with symptoms.
Seoul, SeodaemunAges 50–85 - NCT05176704Recruiting
Eye movement tests for Alzheimer's disease
This study looks at how people with Alzheimer's disease move their eyes compared to healthy people. The goal is to develop simple, non-invasive eye-tracking tests that could help diagnose Alzheimer's disease earlier and more accurately.
Montreal, QuebecAges 18 years+ - NCT07758595RecruitingPhase 1
Study of DNL921 for healthy people and people with Alzheimer's disease
This trial tests an investigational drug called DNL921 in healthy volunteers and in people with mild to moderate Alzheimer's disease. The goal is to see if it is safe and how the body handles it, which is a first step in finding a new treatment.
ManchesterAges 18–75 - NCT07758660Enrolling by invitationPhase 2
Brain scan study for Alzheimer's research
This study uses brain scans (PET) to look at changes in the brain that may be related to memory problems or Alzheimer's disease. It aims to improve understanding of the disease and may help develop better treatments.
New York, New YorkAges 50 years+ - NCT07717411RecruitingPhase 3
Trontinemab for people at risk of Alzheimer's symptoms
This study tests an investigational drug, trontinemab, in people who are cognitively healthy but have a blood marker suggesting a high chance of developing Alzheimer's symptoms later. The goal is to see if the drug can delay or prevent memory loss.
Irvine, CaliforniaAges 55–80 - NCT07694921Enrolling by invitation
Non-invasive brain stimulation for Alzheimer's disease
This trial tests if a safe, non-invasive electrical stimulation can help people with Alzheimer's disease. It aims to improve thinking and memory skills.
Hangzhou, ZhejiangAges 60 years+ - NCT07633470RecruitingPhase 4
Zunveyl for Alzheimer's disease symptoms and caregiver support
This study tests a medication called Zunveyl to see if it helps reduce behavioral and neuropsychiatric symptoms in people with mild-to-moderate Alzheimer's disease, and whether it reduces stress on family caregivers. You would need a confirmed Alzheimer's diagnosis supported by a blood test, and a dedicated caregiver who can attend visits and report on your symptoms.
Irvine, CaliforniaAges 50 years+
Hear when a new Alzheimer's Disease Dementia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alzheimer's disease dementia?
- Yes. Clin2 currently lists 471 recruiting alzheimer's disease dementia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alzheimer's disease dementia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alzheimer's disease dementia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.